co.don AG Logo

co.don AG

Develops personalized cartilage cell transplants for minimally invasive joint repair.

CNW | F

Overview

Corporate Details

ISIN(s):
DE000A3E5C08 (+1 more)
LEI:
3912006R73YW0SX1KG21
Country:
Germany
Address:
Warthestr. 21, 14513 Teltow
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

co.don AG is a biopharmaceutical company specializing in tissue engineering and regenerative medicine. The company focuses on the development, manufacturing, and marketing of autologous cell therapies for the treatment of articular cartilage defects. Its core process involves using a patient's own cartilage cells (chondrocytes) to produce personalized cell transplants, such as spherical cartilage cell implants (spheroids), for the minimally invasive repair of joints. Following an asset purchase in early 2023, the operative business was taken over by an investor and now operates as CO.DON GmbH, a ReLive company, continuing its work in human cell-based therapies.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-09-30 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2022 bis zum 30.0…
German 142.4 KB
2022-09-29 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2022 bis zum 30.06.2022
German 6.4 KB
2022-07-11 00:00
Regulatory News Service
Jahres- und Konzernabschluss zum Geschäftsjahr vom 01.01.2021 bis zum 31.12.2021
German 1.3 MB
2022-07-06 00:00
Report Publication Announcement
Berichtigung der Veröffentlichung vom 14.06.2022
German 6.4 KB
2022-06-14 00:00
Report Publication Announcement
Berichtigt am 06.07.2022
German 6.4 KB
2022-04-29 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2021 bis zum 31.12.2021
German 6.4 KB
2021-09-11 00:00
Director's Dealing
CO.DON AG: Mitteilung über Eigengeschäfte von Führungskräften gem. Art. 19 MAR
German 13.9 KB
2021-08-30 00:00
Interim Report
Halbjahresfinanzbericht
German 148.6 KB
2021-05-27 00:00
Report Publication Announcement
Jahresabschluss zum Geschäftsjahr vom 01.01.2020 bis zum 31.12.2020
German 4.2 KB
2021-05-25 00:00
Annual Report
Konzernabschluss zum Geschäftsjahr vom 01.01.2020 bis zum 31.12.2020
German 4.2 KB
2021-05-22 00:00
Regulatory News Service
Ad-hoc-Meldung gemäß Art. 17 MAR in Verbindung mit § 4 Abs. 1 S. 1 Nr. 1a WpAV
English 11.8 KB
2020-08-28 00:00
Interim Report
Datum:28.08.2020
German 381.2 KB
2020-08-24 00:00
Report Publication Announcement
Datum:24.08.2020
German 12.2 KB
2020-07-28 00:00
Annual Report
Datum:28.07.2020
German 998.8 KB
2020-07-07 00:00
Annual Report
Datum:07.07.2020
German 41.3 KB

Automate Your Workflow. Get a real-time feed of all co.don AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for co.don AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for co.don AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2021-10-20 Laik, Jonathan Close relation Other None 25,994.00 EUR
2021-10-20 Friedrich, Julia Close relation Other None 19,500.00 EUR
2021-10-20 MMI Leisure & Capital Management GmbH Close relation Buy None 4,500.00 EUR
2021-10-19 Seidel, Marcus Supervisory board Buy None 33,105.80 EUR
2021-10-18 Bauerfeind Beteiligungsgesellschaft mbH Close relation Other None 3,882,975.20 EUR
2021-10-18 Bauerfeind Beteiligungsgesellschaft mbH Close relation Other None 1,439,447.10 EUR
2021-10-18 Ceccaldi, Julie Close relation Sell None 23,377.60 EUR
2021-10-18 Pierer Industrie AG Close relation Other None 18,430.00 EUR

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America AARD
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America ABBV
ABEONA THERAPEUTICS INC. Logo
Developing AAV-based cell and gene therapies for serious and rare diseases.
United States of America ABEO
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX

Talk to a Data Expert

Have a question? We'll get back to you promptly.